The governments around the developed world are adapting to an anti-lockdown policy. Living with Covid will lessen the pressure to force vaccination among the populous. Moderna (MRNA) stock is struggling to rise from here as a result.
Moderna’s low price-to-earnings multiple and forward P/E is too low to ignore. Its vaccine saved millions of people from the dangerous variants of Covid in the last two years. Omicron is a milder strain while Omicron’s sub-variant is more contagious but less dangerous. Moderna is not sitting still. Not only did it show that its existing vaccine offers some protection, but it is also developing the next vaccine.
When Moderna shares results from its vaccine specifically targeting Omicron, its potential revenue may grow. Governments may consider an annual vaccine policy. As they order Moderna’s updated vaccine, investors will re-evaluate Moderna’s growth potential.
Moderna, BioNTech (BNTX), and Novavax (NVAX) are among the vaccine suppliers that the world will need to rely on. Covid will become endemic. To get there, countries will need to offer regular vaccinations. This will prevent the virus from becoming a pandemic again.
Investors may guard their portfolio against the risk of another pandemic by considering a position in MRNA stock. Shares are cheap compared to other drug and biotech companies in the healthcare sector.
